Potent, Safer Respiratory Syncytial Virus Therapeutics

Description

This technology is a cutting-edge antiviral technology designed to treat respiratory syncytial virus (RSV) by potently inhibiting RSV RNA synthesis. This technology has shown remarkable efficacy in preclinical mouse models, significantly reducing lung virus load. With the potential for oral administration and reduced toxicity, this breakthrough treatment is a safer, more effective solution for RSV infections and a wide range of other respiratory viruses.

RSV is a leading cause of severe respiratory illness, especially in infants and the elderly. Current RSV therapeutics are limited by toxicity, poor efficacy, or high costs, while newly developed RSV vaccines struggle with low patient adoption. With the growing anti-vax movement and growing viral resistance issues associated with existing antiviral medications, there is an urgent need for more targeted therapies with minimal side effects.

Benefits

• Strong Efficacy: Lead compound demonstrates a 79-fold reduction in lung viral load in preclinical RSV mouse models.
• Safer: Low cytotoxicity and no significant adverse effects at effective doses in both mice and cell line studies.
• Broad-spectrum: Target a wide range of respiratory viruses, including RSV, offering a versatile solution for respiratory viral infections.

Applications

• RSV Therapeutics
• Respiratory Virus Therapeutic Development

Patent Status

• WO2023018560A1 - Bicyclic fused pyrazole derivatives for the treatment of respiratory infections including rsv - Google Patents

Publications

Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase - PubMed